UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022

PROCEPT BIOROBOTICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-40797 (Commission File Number) 26-0199180 (IRS Employer Identification Number)

900 Island Drive Redwood City, California 94065 (Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (650) 232-7200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:							
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)						
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)						
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))						
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))						
Securities registered pursuant to Section 12(b) of the Act:							
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered				
Common Stock, \$0.00001 par value per share		PRCT	The Nasdaq Stock Market LLC				
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).							
Emerging growth company ⊠							
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box							

Item 5.07 Submission of Matters to a Vote of Security Holders.

The annual meeting of stockholders (the "Annual Meeting") of PROCEPT BioRobotics Corporation (the "Company") was held on June 7, 2022.

All of the nominees for director listed in Proposal 1 in the Company's Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 28, 2022 (the "Proxy Statement"), were elected to serve on the Company's board of directors until the Company's 2025 annual meeting of stockholders, or until his or her successor is duly elected or appointed, by the following vote:

Name of Nominee	Votes For	Votes Withheld	Broker Non-Votes
Thomas Krummel, M.D.	27,027,803	1,904,365	3,025,300
Colby Wood	26,993,828	1,938,340	3,025,300
Elisabeth Sandoval-Little	28,901,490	30,678	3,025,300

Proposal 2 in the Proxy Statement, a proposal to ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022, was approved by the following vote:

Votes For	Votes Withheld	Abstentions	
31,955,355	979	1,134	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROCEPT BIOROBOTICS CORPORATION

Date: June 8, 2022 By: /s/ Alaleh Nouri

Alaleh Nouri

Chief Legal Officer and Secretary